文献速递白血病

upfront 贝林妥欧单抗改善成人Ph阴性B系急性淋巴细胞白血病的MRD清除与结局:GIMEMA LAL2317 2期研究

Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.
PubMed 文献 · Blood · 2025-01-01

GIMEMA LAL2317 2期研究评估化疗联合贝林妥欧单抗一线治疗成人Ph阴性CD19阳性B系急性淋巴细胞白血病。149例患者入组,132例达缓解,122例接受贝林妥欧单抗,109例有前后MRD评估。贝林妥欧单抗后MRD阴性率从72%升至93%(P<.001),中位随访38.1个月,3年OS和DFS分别为71%和65%。

要点

  • 贝林妥欧单抗后MRD阴性率从72%升至93%(P<.001),30例MRD阳性中23例(73%)转阴,达主要终点。
  • 中位随访38.1个月,中位OS和DFS未达到,估计3年OS和DFS分别为71%和65%。
  • 贝林妥欧单抗治疗患者3年生存率为82%,仅8例因毒性永久停药。

核心结论

  • 化疗-贝林妥欧单抗风险导向方案在成人Ph阴性B-ALL中取得显著结果,但早期MRD持续的高危患者仍需进一步改善。
  • 作者认为贝林妥欧单抗应被视为成人Ph阴性B-ALL诱导/巩固治疗的标准组成部分。

研究设计与样本

  • GIMEMA LAL2317 2期研究,评估化疗联合贝林妥欧单抗一线治疗成人Ph阴性CD19阳性B系急性淋巴细胞白血病。
  • 化疗第3和第6周期后给予2个周期静脉贝林妥欧单抗。
  • 主要终点为贝林妥欧单抗1后分子MRD阴性率。
  • 149例患者入组(中位年龄41岁,范围18-65岁);132例达缓解,122例接受贝林妥欧单抗,109例有贝林妥欧单抗1前后MRD评估。

主要发现

  • 贝林妥欧单抗后MRD阴性率从72%升至93%(P<.001),30例MRD阳性患者中23例(73%)转为MRD阴性。
  • 中位随访38.1个月(范围0.5-62.8),中位OS和DFS未达到,估计3年OS和DFS分别为71%和65%。
  • 18至40岁且早期达MRD阴性的患者DFS为92%。
  • 贝林妥欧单抗治疗患者3年生存率为82%。
  • 标准化疗组、造血干细胞移植组和移植受者的生存率与复发率分别为91%和15%、59%和35%、69%和19%。

关键数值与推荐

  • MRD阴性率从72%升至93%(P<.001)。
  • 估计3年OS为71%,3年DFS为65%。
  • 贝林妥欧单抗治疗患者3年生存率为82%。
  • 18至40岁且早期MRD阴性患者DFS为92%。
  • 标准化疗组生存率91%、复发率15%;造血干细胞移植组生存率59%、复发率35%;移植受者生存率69%、复发率19%。

临床怎么用

  • 作者认为贝林妥欧单抗应被视为成人Ph阴性B-ALL诱导/巩固治疗的标准组成部分。
  • 贝林妥欧单抗1前MRD阳性预示更差结局,尤其在遗传学高危患者中。

局限性

  • 早期MRD持续的高危患者结果仍需进一步改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Leucemia Acuta Linfoblastica (LAL) 2317 protocol investigated the frontline chemotherapy-blinatumomab combination in adult Philadelphia chromosome/BCR::ABL1 rearrangement-negative (Ph-) CD19+ B-lineage acute lymphoblastic leukemia (B-ALL) to improve minimal residual disease (MRD) response and clinical outcome. Two cycles of IV blinatumomab were administered after chemotherapy cycles 3 and 6. The primary end point was the rate of molecular MRD negativity after blinatumomab 1. One hundred forty-nine patients were enrolled (median age, 41 years [range, 18-65]); 132 entered remission, 122 received blinatumomab, and 109 had a pre- and post-blinatumomab 1 MRD assessment. MRD negativity increased from 72% to 93% (P < .001) after blinatumomab, with 23 of 30 MRD-positive patients (73%) becoming MRD negative, fulfilling the primary end point. At a median follow-up of 38.1 months (range, 0.5-62.8), the median overall survival (OS) and disease-free survival (DFS) were not reached, and the estimated 3-year OS and DFS were 71% and 65%, respectively, with an excellent outlook for the patients aged 18 to 40 years who achieved an early MRD negativity (DFS, 92%). Pre-blinatumomab MRD predicted a worse outcome, especially in genetically high-risk patients. Notably, the 3-year survival of blinatumomab-treated patients was 82%. Survival and relapse rates were 91% and 15% in patients assigned to standard chemotherapy, 59% and 35% in patients assigned to hematopoietic stem cell transplantation, and 69% and 19% in transplant recipients, respectively. Blinatumomab toxicity was manageable, with only 8 permanent discontinuations. This chemotherapy-blinatumomab risk-oriented program yielded remarkable results that need further improvement in higher-risk patients displaying early MRD persistence. Blinatumomab should be considered as a standard component of induction/consolidation for adult Ph- B-ALL. This trial was registered at www.ClinicalTrials.gov as #NCT03367299.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bassan R, Chiaretti S, Della Starza I, et al. Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study. Blood. 2025. PMID: 40009490. doi:10.1182/blood.2024027500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。